DUBLIN--(BUSINESS WIRE)--Apr. 21, 2016--
Alkermes
plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT
(1:30 p.m. BST) on Thursday, April 28, 2016, to discuss the company’s
first quarter 2016 financial results. Management will also provide an
update on the company.
The conference call will be webcast on the Investors section of
Alkermes’ website at www.alkermes.com
or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1
847 585 4422 for international callers. The conference call ID number is
6037988.
A replay of the conference call will be available from 11:00 a.m. EDT
(4:00 p.m. BST) on Thursday, April 28, 2016, through 5:00 p.m. EDT
(10:00 p.m. BST) on Thursday, May 5, 2016, and may be accessed by
visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S.
callers and +1 630 652 3042 for international callers. The replay access
code is 6037988.
About Alkermes plc
Alkermes
plc is a fully integrated, global biopharmaceutical company developing
innovative medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product portfolio and
a substantial clinical pipeline of product candidates for chronic
diseases that include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts; a research and manufacturing facility
in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
For more information, please visit Alkermes’ website at www.alkermes.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160421006339/en/
Source: Alkermes plc
Alkermes
Sandra Coombs, +1 781 609 6377
Corporate
Communications